Abstract

BackgroundMitochondrial DNA (mtDNA) copy number decreases in animal and human heart failure (HF), yet its role in cardiomyocytes remains to be elucidated. Thus, we investigated the cardioprotective function of increased mtDNA copy number resulting from the overexpression of human transcription factor A of mitochondria (TFAM) or Twinkle helicase in volume overload (VO)-induced HF.Methods and ResultsTwo strains of transgenic (TG) mice, one overexpressing TFAM and the other overexpressing Twinkle helicase, exhibit an approximately 2-fold equivalent increase in mtDNA copy number in heart. These TG mice display similar attenuations in eccentric hypertrophy and improved cardiac function compared to wild-type (WT) mice without any deterioration of mitochondrial enzymatic activities in response to VO, which was accompanied by a reduction in matrix-metalloproteinase (MMP) activity and reactive oxygen species after 8 weeks of VO. Moreover, acute VO-induced MMP-2 and MMP-9 upregulation was also suppressed at 24 h in both TG mice. In isolated rat cardiomyocytes, mitochondrial reactive oxygen species (mitoROS) upregulated MMP-2 and MMP-9 expression, and human TFAM (hTFAM) overexpression suppressed mitoROS and their upregulation. Additionally, mitoROS were equally suppressed in H9c2 rat cardiomyoblasts that overexpress hTFAM or rat Twinkle, both of which exhibit increased mtDNA copy number. Furthermore, mitoROS and mitochondrial protein oxidation from both TG mice were suppressed compared to WT mice.ConclusionsThe overexpression of TFAM or Twinkle results in increased mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. Our findings suggest that increasing mtDNA copy number could be a useful therapeutic strategy to target mitoROS in HF.

Highlights

  • Heart failure (HF) continues to be an unsolved problem in developed countries.[1]

  • Two strains of transgenic (TG) mice, one overexpressing transcription factor A of mitochondria (TFAM) and the other overexpressing Twinkle helicase, exhibit an approximately 2-fold equivalent increase in Mitochondrial DNA (mtDNA) copy number in heart. These TG mice display similar attenuations in eccentric hypertrophy and improved cardiac function compared to wild-type (WT) mice without any deterioration of mitochondrial enzymatic activities in response to volume overload (VO), which was accompanied by a reduction in matrix-metalloproteinase (MMP) activity and reactive oxygen species after 8 weeks of VO

  • The overexpression of TFAM or Twinkle results in increased mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress

Read more

Summary

Introduction

Heart failure (HF) continues to be an unsolved problem in developed countries.[1]. During HF, hemodynamic load and neuro-hormonal activation cause structural and functional alterations of the heart, which start initially as adaptive responses, but later become maladaptive, and eventually lead to the vicious cycle of HF.[2]. Mitochondrial transcription factor A (TFAM), which was initially cloned as an mtDNA transcription factor, plays an essential role in the maintenance of mtDNA and mitochondrial homeostasis.[8,9] Heart-specific TFAM knockout mice present with a critical depletion in mtDNA copy number, progressive respiratory chain deficiency in the myocardium, and lethality due to severe cardiac dysfunction.[10,11] In contrast, TFAM overexpression increases mtDNA copy number, ameliorates cardiac remodeling, and improves the survival after myocardial infarction (MI) in mice.[12] the precise roles and the protective mechanisms of mtDNA quantity in HF remain to be elucidated. Mitochondrial DNA (mtDNA) copy number decreases in animal and human heart failure (HF), yet its role in cardiomyocytes remains to be elucidated. We investigated the cardioprotective function of increased mtDNA copy number resulting from the overexpression of human transcription factor A of mitochondria (TFAM) or Twinkle helicase in volume overload (VO)-induced HF

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.